Literature DB >> 12521357

Pharmacological treatment of vertigo.

Timothy C Hain1, Mohammed Uddin.   

Abstract

This review discusses the physiology and pharmacological treatment of vertigo and related disorders. Classes of medications useful in the treatment of vertigo include anticholinergics, antihistamines, benzodiazepines, calcium channel antagonists and dopamine receptor antagonists. These medications often have multiple actions. They may modify the intensity of symptoms (e.g. vestibular suppressants) or they may affect the underlying disease process (e.g. calcium channel antagonists in the case of vestibular migraine). Most of these agents, particularly those that are sedating, also have a potential to modulate the rate of compensation for vestibular damage. This consideration has become more relevant in recent years, as vestibular rehabilitation physical therapy is now often recommended in an attempt to promote compensation. Accordingly, therapy of vertigo is optimised when the prescriber has detailed knowledge of the pharmacology of medications being administered as well as the precise actions being sought. There are four broad causes of vertigo, for which specific regimens of drug therapy can be tailored. Otological vertigo includes disorders of the inner ear such as Ménière's disease, vestibular neuritis, benign paroxysmal positional vertigo (BPPV) and bilateral vestibular paresis. In both Ménière's disease and vestibular neuritis, vestibular suppressants such as anticholinergics and benzodiazepines are used. In Ménière's disease, salt restriction and diuretics are used in an attempt to prevent flare-ups. In vestibular neuritis, only brief use of vestibular suppressants is now recommended. Drug treatments are not presently recommended for BPPV and bilateral vestibular paresis, but physical therapy treatment can be very useful in both. Central vertigo includes entities such as vertigo associated with migraine and certain strokes. Prophylactic agents (L-channel calcium channel antagonists, tricyclic antidepressants, beta-blockers) are the mainstay of treatment for migraine-associated vertigo. In individuals with stroke or other structural lesions of the brainstem or cerebellum, an eclectic approach incorporating trials of vestibular suppressants and physical therapy is recommended. Psychogenic vertigo occurs in association with disorders such as panic disorder, anxiety disorder and agoraphobia. Benzodiazepines are the most useful agents here. Undetermined and ill-defined causes of vertigo make up a large remainder of diagnoses. An empirical approach to these patients incorporating trials of medications of general utility, such as benzodiazepines, as well as trials of medication withdrawal when appropriate, physical therapy and psychiatric consultation is suggested.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12521357     DOI: 10.2165/00023210-200317020-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  86 in total

1.  Transdermal scopolamine withdrawal syndrome.

Authors:  R E Feder
Journal:  Clin Neuropharmacol       Date:  1999 Mar-Apr       Impact factor: 1.592

Review 2.  The pathways and functions of GABA in the oculomotor system.

Authors:  R F Spencer; S F Wang; R Baker
Journal:  Prog Brain Res       Date:  1992       Impact factor: 2.453

3.  Vestibular compensation in a patient with a cerebellar infarction.

Authors:  J M Furman; C D Balaban; I F Pollack
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

4.  Antiemetic effects of serotonergic 5-HT1A-receptor agonists in Suncus murinus.

Authors:  F Okada; Y Torii; H Saito; N Matsuki
Journal:  Jpn J Pharmacol       Date:  1994-02

5.  New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study.

Authors:  Carlo Pane Pianese; Lourdes Olivia Vales Hidalgo; Ramón Hinojosa González; Cecilia Esteinou Madrid; Jorge Enrique Cruz Ponce; Alberto Mañé Ramírez; Luis Martínez Morán; José Enrique Poó Arenas; Arturo Torres y Gutiérrez Rubio; Jorge Olguin Uribe; José Abiuso; Enrique Hanuch; Juan Alegría; Claudio Volpi; Renate Flaskamp; Augusto Peñaranda Sanjuán; Juan Manuel García Gómez; Jaime Hernández; Alvaro Pedraza; Diana Quijano; Carolina Martínez; Juan Ramón Castañeda; Oscar Jorge Cardeñosa Guerra; G Valencia F
Journal:  Otol Neurotol       Date:  2002-05       Impact factor: 2.311

6.  Maxi K+ channel in apical membrane of vestibular dark cells.

Authors:  S Takeuchi; D C Marcus; P Wangemann
Journal:  Am J Physiol       Date:  1992-06

7.  Betahistine increases vestibular blood flow.

Authors:  J K Dziadziola; E L Laurikainen; J D Rachel; W S Quirk
Journal:  Otolaryngol Head Neck Surg       Date:  1999-03       Impact factor: 3.497

8.  Effects of betahistine on vestibular receptors of the frog.

Authors:  L Botta; E Mira; S Valli; P Perin; G Zucca; P Valli
Journal:  Acta Otolaryngol       Date:  1998-07       Impact factor: 1.494

9.  Muscarinic antagonists in the treatment of acquired pendular and downbeat nystagmus: a double-blind, randomized trial of three intravenous drugs.

Authors:  J J Barton; A G Huaman; J A Sharpe
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

10.  The prevalence of migraine in Menière's disease.

Authors:  C H Rassekh; L A Harker
Journal:  Laryngoscope       Date:  1992-02       Impact factor: 3.325

View more
  23 in total

1.  Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.

Authors:  Jozef J P Nauta
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-19       Impact factor: 2.503

Review 2.  Teaching Patient-Centered Counseling Skills for Assessment, Diagnosis, and Management of Benign Paroxysmal Positional Vertigo.

Authors:  Anna Marie Jilla; Richard A Roberts; Carole E Johnson
Journal:  Semin Hear       Date:  2018-02-07

3.  Effects of cinnarizine on calcium and pressure-dependent potassium currents in guinea pig vestibular hair cells.

Authors:  Philip Düwel; Thorsten Haasler; Eberhard Jüngling; Thien An Duong; Martin Westhofen; Andreas Lückhoff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-23       Impact factor: 3.000

4.  Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure.

Authors:  Mohamed A Kamal; David E Smith; Jack Cook; Douglas Feltner; Allen Moton; Daniele Ouellet
Journal:  J Pharm Sci       Date:  2010-08       Impact factor: 3.534

5.  Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study.

Authors:  Arne-Wulf Scholtz; Raluca Steindl; Nicole Burchardi; Irene Bognar-Steinberg; Wolfgang Baumann
Journal:  Clin Drug Investig       Date:  2012-06-01       Impact factor: 2.859

6.  Neuropharmacology of vestibular system disorders.

Authors:  Enrique Soto; Rosario Vega
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

7.  Benign paroxysmal positional vertigo.

Authors:  Seung-Han Lee; Ji Soo Kim
Journal:  J Clin Neurol       Date:  2010-06-30       Impact factor: 3.077

8.  Postsynaptic mechanisms underlying the excitatory action of histamine on medial vestibular nucleus neurons in rats.

Authors:  Xiao-Yang Zhang; Lei Yu; Qian-Xing Zhuang; Shi-Yu Peng; Jing-Ning Zhu; Jian-Jun Wang
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

9.  A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders : a randomized, reference-controlled clinical study.

Authors:  Ales Hahn; Ivan Sejna; Bohdana Stefflova; Mario Schwarz; Wolfgang Baumann
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

10.  Vestibular rehabilitation outcomes in patients with and without vestibular migraine.

Authors:  Jessica Vitkovic; Arimbi Winoto; Gary Rance; Richard Dowell; Mark Paine
Journal:  J Neurol       Date:  2013-09-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.